FDA 483 - Megafine Pharma (P) Limited - January 24, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
This FDA Form 483 report details significant deficiencies at Megafine Pharma (P) Ltd. related to their manufacturing of Active Pharmaceutical Ingredients (APIs). The firm's quality unit failed to ensure CGMP compliance, with issues spanning inadequate cleaning validation, poor data integrity practices, and ineffective investigation processes. Observations also highlight problems with equipment maintenance, non-contemporaneous batch record keeping, and insufficient controls in packaging and laboratory operations.
ID · 7a2c4604-b9fa-43d7-a7ca-54c6b802002c